CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Gabapentin for HIV-Associated Neuropathic Pain: Clinical Effectiveness

Last updated: November 25, 2015
Project Number: RA0817-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain?

Key Message

One systematic review, one randomized controlled trial, and one non-randomized study were identified regarding the clinical effectiveness of gabapentin for the treatment of HIV-associated neuropathic pain.